Toll‐like receptors: The role in bladder cancer development, progression and immunotherapy

The Role of TLR4 Asp299Gly and TLR4 Thr399Ile Polymorphisms in the Pathogenesis of Urinary Tract Infections: First Evaluation in Infants and Children of Greek Origin

(2019) Panagiota Karananou et al.   Journal of Immunology Research

Differential responses of epithelial cells from urinary and biliary tract to eggs of Schistosoma haematobium and S. mansoni

(2019) Rafael Nacif-Pimenta et al.   Scientific Reports

HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer

(2018) Tristan A Barnes et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents

(2018) Nataša Obermajer et al.   Nature Protocols

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook

(2018) Dharmesh Gopalakrishnan et al.   Therapeutics and Clinical Risk Management

TLR-3 Stimulation Skews M2 Macrophages to M1 Through IFN-αβ Signaling and Restricts Tumor Progression

(2018) Aurobind Vidyarthi et al.   Frontiers in Immunology

Bladder Cancer: New Insights into Its Molecular Pathology

(2018) Kentaro Inamura   Cancers

TLR8 and its endogenous ligand miR-21 contribute to neuropathic pain in murine DRG

(2018) Zhi-Jun Zhang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Schistosomiasis

(2018) Richard Barnett   LANCET

Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation

(2018) Elisabeth Müller et al.   Frontiers in Immunology

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy

(2017) Yang‐Min Ning et al.   ONCOLOGIST

Nivolumab Gets FDA Nod for Bladder Cancer

(2017)   Cancer Discovery

The role of toll-like receptor 4 in tumor microenvironment

(2017) Jing Li et al.   Oncotarget

A new model of self-resolving leptospirosis in mice infected with a strain of Leptospira interrogans serovar Autumnalis harboring LPS signaling only through TLR4

(2017) Bili Xia et al.   Emerging Microbes & Infections

Anti-tumor Activity of Toll-Like Receptor 7 Agonists

(2017) Huju Chi et al.   Frontiers in Pharmacology

TLR7 Deficiency Leads to TLR8 Compensative Regulation of Immune Response against JEV in Mice

(2017) Muhammad Awais et al.   Frontiers in Immunology

Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages

(2017) Elisabeth Müller et al.   Frontiers in Immunology

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

(2017) Thomas Powles et al.   JAMA Oncology

CTLA-4 and PD-1 Pathways

(2016) Elizabeth I. Buchbinder et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier

(2016) Patrick Vianna Garcia et al.   BMC CANCER

Double-Stranded RNA Interacts With Toll-Like Receptor 3 in Driving the Acute Inflammatory Response Following Lung Contusion

(2016) Madathilparambil V. Suresh et al.   CRITICAL CARE MEDICINE

Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin

(2016) Ashish M. Kamat et al.   EUROPEAN UROLOGY

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours

(2016) Peter A. Humphrey et al.   EUROPEAN UROLOGY

Future directions in bladder cancer immunotherapy: towards adaptive immunity

(2016) Sean G Smith et al.   Immunotherapy

CBLB502, an agonist of Toll-like receptor 5, has antioxidant and scavenging free radicals activities in vitro

(2016) Weiguang Li et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer

(2016) Renate Pichler et al.   Oncotarget

Toll-like Receptor 9 Can be Activated by Endogenous Mitochondrial DNA to Induce Podocyte Apoptosis

(2016) Wenduona Bao et al.   Scientific Reports

Estrogen-like metabolites and DNA-adducts in urogenital schistosomiasis-associated bladder cancer

(2015) Maria João Gouveia et al.   CANCER LETTERS

Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise

(2015) J. Kim et al.   CLINICAL CANCER RESEARCH

Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder

(2015) Philip H. Kim et al.   EUROPEAN UROLOGY

Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?

(2015) Srinath Sundararajan et al.   Future Oncology

Nivolumab: targeting PD-1 to bolster antitumor immunity

(2015) Julie R Brahmer et al.   Future Oncology

Molecular Biology of Bladder Cancer

(2015) William Martin-Doyle et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Association of TLR1, TLR2, TLR4, TLR6, and TIRAP polymorphisms with disease susceptibility

(2015) Mamoona Noreen et al.   IMMUNOLOGIC RESEARCH

Imiquimod - Its role in the treatment of cutaneous malignancies

(2015) AdityaKumar Bubna   INDIAN JOURNAL OF PHARMACOLOGY

Bacille Calmette-Guerin can induce cellular apoptosis of urothelial cancer directly through toll-like receptor 7 activation

(2015) Dah-Shyong Yu et al.   KAOHSIUNG JOURNAL OF MEDICAL SCIENCES

Toll-like receptor agonist lipopeptides self-assemble into distinct nanostructures

(2014) Ian W. Hamley et al.   CHEMICAL COMMUNICATIONS

RNA and Imidazoquinolines Are Sensed by Distinct TLR7/8 Ectodomain Sites Resulting in Functionally Disparate Signaling Events

(2014) E. Colak et al.   JOURNAL OF IMMUNOLOGY

Comprehensive molecular characterization of urothelial bladder carcinoma

(2014)   NATURE

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Toll-Like Receptor Signaling Pathways

(2014) Takumi Kawasaki et al.   Frontiers in Immunology

Tumor-Associated Macrophages as a Paradigm of Macrophage Plasticity, Diversity, and Polarization

(2013) Alberto Mantovani et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

TLR9 Signaling in the Tumor Microenvironment Initiates Cancer Recurrence after Radiotherapy

(2013) C. Gao et al.   CANCER RESEARCH

T-cell tolerance in cancer

(2013) Roza Nurieva et al.   Immunotherapy

TLR agonists: our best frenemy in cancer immunotherapy

(2013) Sabina Kaczanowska et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Toll-like Receptor 4 (TLR4) Modulation by Synthetic and Natural Compounds: An Update

(2013) Francesco Peri et al.   JOURNAL OF MEDICINAL CHEMISTRY

From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa

(2013) M A Ingersoll et al.   Mucosal Immunology

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

Toll-like receptors in urothelial cells—targets for cancer immunotherapy

(2013) Hélène LaRue et al.   Nature Reviews Urology

The Herpes Simplex Virus 1-Encoded Envelope Glycoprotein B Activates NF-κB through the Toll-Like Receptor 2 and MyD88/TRAF6-Dependent Signaling Pathway

(2013) Mingsheng Cai et al.   PLoS One

The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure11The first author has a PhD Grant (SFRH/BD/43399/2008) and J.A.F. has a Postdoctoral Grant (SFRH/BPD/66288/2009) from FCT—Fundação para a Ciência e Tecnologia, co-financed by European Social Fund (ESF) under Human Potential Operation Programme (POPH) from National Strategic Reference Framework (NSRF). We thank to LPCC, Portuguese League Against Cancer (NRNorte) for their support. This work was also supported by Fundação para a Ciência e a Tecnologia (FCT, Portugal), European Union, QREN, FEDER and COMPETE for funding the QOPNA research unit (project PEst-C/QUI/UI0062/2013).2Both authors have equally contributed to the work.

(2013) Luís Lima et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Single-nucleotide Polymorphisms in Genes Encoding Toll-like Receptor -2, -3, -4, and -9 in a Case–Control Study with Bladder Cancer Susceptibility in a North Indian Population

(2012) Vibha Singh et al.   ARCHIVES OF MEDICAL RESEARCH

Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense

(2012) Shaherin Basith et al.   ARCHIVES OF PHARMACAL RESEARCH

Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis

(2012) Baerin B. Houghton et al.   BJU INTERNATIONAL

The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature

(2012) R. J. deLeeuw et al.   CLINICAL CANCER RESEARCH

The application of Toll like receptors for cancer therapy

(2012) Eui Young So et al.   International Journal of Biological Sciences

U1-Small Nuclear Ribonucleoprotein Activates the NLRP3 Inflammasome in Human Monocytes

(2012) M. S. Shin et al.   JOURNAL OF IMMUNOLOGY

Results of a Phase 1 Dose Escalation Study of Intravesical TMX-101 in Patients with Nonmuscle Invasive Bladder Cancer

(2012) Johannes Falke et al.   JOURNAL OF UROLOGY

Toll-like Receptor 4 Gene Polymorphisms and Susceptibility to Bladder Cancer

(2012) Yizhen Shen et al.   PATHOLOGY & ONCOLOGY RESEARCH

Prognostic Value of Cell-Cycle Regulation Biomarkers in Bladder Cancer

(2012) Anirban P. Mitra et al.   SEMINARS IN ONCOLOGY

Germline prognostic markers for urinary bladder cancer: Obstacles and opportunities

(2012) David W. Chang et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Poly (I:C), an agonist of toll-like receptor-3, inhibits replication of the Chikungunya virus in BEAS-2B cells

(2012) Yong-Gang Li et al.   Virology Journal

HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response

(2011) Gaia Codolo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Akt signalling in health and disease

(2011) Ingeborg Hers et al.   CELLULAR SIGNALLING

A delicate dance: host response to mycobacteria

(2011) Kassidy K Huynh et al.   CURRENT OPINION IN IMMUNOLOGY

179 A PRECLINICAL PLACEBO CONTROLLED EFFICACY STUDY WITH R-837 AND TMX-202 IN AN ORTHOTOPIC RAT BLADDER CANCER MODEL

(2011) J. Falke et al.   EUROPEAN UROLOGY SUPPLEMENTS

TLR4 dependent heparan sulphate-induced pancreatic inflammatory response is IRF3-mediated

(2011) Hamid Akbarshahi et al.   Journal of Translational Medicine

Toll-Like Receptors in Normal and Malignant Human Bladders

(2011) Cherifa Ayari et al.   JOURNAL OF UROLOGY

Toll-Like Receptor Responses of Normal Human Urothelial Cells to Bacterial Flagellin and Lipopolysaccharide

(2011) Nicholas J. Smith et al.   JOURNAL OF UROLOGY

Immunolocalization of Toll-Like Receptors 2 and 4 as well as Their Endogenous Ligand, Heat Shock Protein 70, in Rat Traumatic Brain Injury

(2011) Zhiren Zhang et al.   NEUROIMMUNOMODULATION

The Structural Biology of Toll-like Receptors

(2011) Istvan Botos et al.   STRUCTURE

Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma

(2011) Ilyar Sheyhidin   WORLD JOURNAL OF GASTROENTEROLOGY

Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis

(2010) Salomé González-Reyes et al.   BMC CANCER

Toll-like receptor 2 is present in the microenvironment of oral squamous cell carcinoma

(2010) L K Ng et al.   BRITISH JOURNAL OF CANCER

Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence

(2010) Salomé González-Reyes et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Combined Gene Expression and Genomic Profiling Define Two Intrinsic Molecular Subtypes of Urothelial Carcinoma and Gene Signatures for Molecular Grading and Outcome

(2010) David Lindgren et al.   CANCER RESEARCH

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

(2010) B. C. Carthon et al.   CLINICAL CANCER RESEARCH

Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression

(2010) Martin Grimm et al.   EUROPEAN JOURNAL OF CANCER

Intravesical Toll-like receptor 7 agonist R-837: Optimization of its formulation in an orthotopic mouse model of bladder cancer

(2010) Tomoko Hayashi et al.   INTERNATIONAL JOURNAL OF UROLOGY

Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance

(2010) Julien Cherfils-Vicini et al.   JOURNAL OF CLINICAL INVESTIGATION

Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy

(2010) Sara M. Mangsbo et al.   JOURNAL OF IMMUNOTHERAPY

The Peptide Sequence of Diacyl Lipopeptides Determines Dendritic Cell TLR2-Mediated NK Activation

(2010) Masahiro Azuma et al.   PLoS One

Regulation and Function of NF-κB Transcription Factors in the Immune System

(2009) Sivakumar Vallabhapurapu et al.   Annual Review of Immunology

CpG Oligodeoxyneucleotides as TLR9 Agonists

(2009) Yanal M. Murad et al.   BIODRUGS

Toll-like receptor expression in normal ovary and ovarian tumors

(2009) Mingfu Zhou et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses

(2009) T. H. Mogensen   CLINICAL MICROBIOLOGY REVIEWS

Toll-like receptor agonists in cancer therapy

(2009) Sylvia Adams   Immunotherapy

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Requirement for DNA CpG Content in TLR9-Dependent Dendritic Cell Activation Induced by DNA-Containing Immune Complexes

(2009) K. Yasuda et al.   JOURNAL OF IMMUNOLOGY

CpG Therapy is Superior to BCG in an Orthotopic Bladder Cancer Model and Generates CD4+ T-cell Immunity

(2009) Sara M. Mangsbo et al.   JOURNAL OF IMMUNOTHERAPY

Toll-Like Receptor Polymorphisms and Susceptibility to Urinary Tract Infections in Adult Women

(2009) Thomas R. Hawn et al.   PLoS One

Genetic Variation of the Human Urinary Tract Innate Immune Response and Asymptomatic Bacteriuria in Women

(2009) Thomas R. Hawn et al.   PLoS One

TLR4 Signaling Induces B7-H1 Expression Through MAPK Pathways in Bladder Cancer Cells

(2008) Yigang Qian et al.   CANCER INVESTIGATION

Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors

(2008) Masashi Murata   CANCER SCIENCE

TLR-mediated immune responses in the urinary tract

(2008) Jeongmin Song et al.   CURRENT OPINION IN MICROBIOLOGY

Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer

(2008) Marc Colombel et al.   EUROPEAN UROLOGY SUPPLEMENTS

Evolution of intravesical immunotherapy for bladder cancer: mycobacterial cell wall preparation as a promising agent

(2008) Alvaro Morales   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling

(2008) Yigang Qian et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Increased expression of Toll-like receptors 4 and 9 in human lung cancer

(2008) Yan-Bei Zhang et al.   MOLECULAR BIOLOGY REPORTS

Polymorphisms in Toll-like receptor genes and risk of cancer

(2008) E M El-Omar et al.   ONCOGENE

Mycobacterium bovis BCG Toll-Like Receptors 2 and 4 Cooperation Increases the Innate Epithelial Immune Response

(2007) Patricia Méndez-Samperio et al.   ARCHIVES OF MEDICAL RESEARCH